跳至主要内容
临床试验/NCT00783042
NCT00783042已完成早期 1 期

A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Transthoracic Doppler Echocardiography Method as a Non-Invasive Method for Coronary Function Measurements; Ability to Detect Short-Term Statin Effects in Patients With Increased Cardiovascular Risk

AstraZeneca1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2008年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
已完成
发起方
AstraZeneca
入组人数
80
试验地点
1
主要终点
Change in CFR peak velocity within rosuvastatin group after 1 month of treatment compared to baseline

研究概览

简要总结

The aim of this study is to investigate whether the non-invasive ultrasound method for assessment of coronary blood flow, transthoracic Doppler echocardiography-coronary flow reserve (TTDE-CFR), can be used to measure drug effects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
45 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males aged 45-75 years or females aged 60-75 years inclusive
  • Carotid and/or femoral atherosclerotic plaque, as assessed by carotid ultrasound examination within the last 5 years
  • Abnormal concentrations of lipids or lipoproteins in the blood
  • Provision of signed informed consent

排除标准

  • Treatment with statins or other lipid-lowering drugs, e.g. fibrates, nicotinic acid, cholesterol absorption inhibitor, within the last 6 months before randomisation
  • Current smoking or snuff tobacco use
  • Major CV event (myocardial infarction (MI), stroke/ transitory ischemic attack (TIA), Acute Coronary Syndrome (ACS), revascularisation) within the last 6 months before randomisation
  • Symptomatic carotid stenosis, atrioventricular (AV) block, QT-prolongation, atrial fibrillation, sinus node disease (such as sick sinus syndrome or symptomatic bradycardia), chronic obstructive pulmonary disease (COPD) or asthma

研究组 & 干预措施

1

Active Comparator

干预措施: Rosuvastatin (Drug)

2

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Change in CFR peak velocity within rosuvastatin group after 1 month of treatment compared to baseline

时间窗: Baseline and after 1 month of treatment

Comparison of treatment effects on CFR peak velocities between groups after 1 month of treatment

时间窗: Baseline and after 1 month of treatment

次要结局

  • Changes in CFR peak velocity within the rosuvastatin group after 3 months compared to baseline and to 1 month(Bseline, after 1 month and after 3 months of treatment)
  • Changes in other CFR parameters after one month rosuvastatin or placebo treatment; comparisons within groups and between groups(Baseline and after 1 month of treatment)
  • Changes in plasma lipids, lipoproteins and other cardiovascular biomarkers after 1 month of treatment with rosuvastatin or placebo; comparisons within groups and between groups(Baseline and after 1 month of treatment)

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验